Kevin DeGeeter
Stock Analyst at Oppenheimer
(2.80)
# 1,921
Out of 4,761 analysts
43
Total ratings
33.33%
Success rate
52.16%
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $1.13 | +1,846.90% | 1 | Apr 19, 2022 | |
| ORIC ORIC Pharmaceuticals | Downgrades: Perform | n/a | $7.68 | - | 1 | Mar 22, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $4.72 | +409.01% | 4 | Feb 25, 2022 | |
| NVCR NovoCure | Upgrades: Outperform | $98 | $22.09 | +343.64% | 3 | Feb 2, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $16.46 | +659.42% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $1.86 | +867.74% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $4.12 | +361.17% | 1 | Nov 19, 2021 | |
| SPRO Spero Therapeutics | Downgrades: Perform | n/a | $0.83 | - | 1 | Oct 1, 2021 | |
| PRTG Portage Biotech | Initiates: Outperform | $600 | $4.57 | +13,029.10% | 1 | Sep 21, 2021 | |
| PANW Palo Alto Networks | Maintains: Outperform | $75 → $79 | $191.03 | -58.56% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $161 → $155 | $49.26 | +214.66% | 2 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.45 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $4.53 | +451.88% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $255 | $0.34 | +74,900.00% | 1 | Apr 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,800 | $2.53 | +71,046.25% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $52.00 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.61 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $10.47 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $0.31 | +15,956.52% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $5.36 | +16,691.04% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $7.99 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $225 | $21.54 | +944.57% | 1 | Apr 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $14.18 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $4.18 | - | 2 | Jan 4, 2017 |
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $1.13
Upside: +1,846.90%
ORIC Pharmaceuticals
Mar 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $7.68
Upside: -
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $4.72
Upside: +409.01%
NovoCure
Feb 2, 2022
Upgrades: Outperform
Price Target: $98
Current: $22.09
Upside: +343.64%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $16.46
Upside: +659.42%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $1.86
Upside: +867.74%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $4.12
Upside: +361.17%
Spero Therapeutics
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $0.83
Upside: -
Portage Biotech
Sep 21, 2021
Initiates: Outperform
Price Target: $600
Current: $4.57
Upside: +13,029.10%
Palo Alto Networks
Aug 24, 2021
Maintains: Outperform
Price Target: $75 → $79
Current: $191.03
Upside: -58.56%
Jul 29, 2021
Maintains: Outperform
Price Target: $161 → $155
Current: $49.26
Upside: +214.66%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $0.45
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $4.53
Upside: +451.88%
Apr 30, 2021
Initiates: Outperform
Price Target: $255
Current: $0.34
Upside: +74,900.00%
Mar 2, 2021
Initiates: Outperform
Price Target: $1,800
Current: $2.53
Upside: +71,046.25%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $52.00
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.61
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $10.47
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $50
Current: $0.31
Upside: +15,956.52%
Apr 8, 2020
Initiates: Outperform
Price Target: $900
Current: $5.36
Upside: +16,691.04%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $7.99
Upside: -
Apr 12, 2017
Initiates: Buy
Price Target: $225
Current: $21.54
Upside: +944.57%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $14.18
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $4.18
Upside: -